United-Guardian
Develops specialty ingredients, pharmaceuticals, and medical lubricants through Guardian Laboratories.
Something off on this page? Send us feedback.
Profile
Develops and markets specialty cosmetic, personal-care, and sexual-wellness ingredients alongside pharmaceuticals and medical lubricants. Guardian Laboratories' Lubrajel and Renacidin lines account for nearly all sales, making those product families central to the business.
Through Guardian Laboratories, develops, manufactures, and markets specialty cosmetic, personal-care, and sexual-wellness ingredients, as well as healthcare products including pharmaceuticals and medical lubricants. Its R&D work develops new ingredients and refines or expands uses for existing products.
Lubrajel and Renacidin are the two central product lines, together accounting for nearly all sales. Product innovation is the company's stated operating focus, supported by a collaborative R&D environment and efforts to retain technical talent.
Operations are based in Hauppauge, New York. The business is structurally dependent on the continued performance of the Lubrajel and Renacidin product families.
Company facts
Key statistics
Year to date +15.8% · Average volume (30d) 10.6K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | — | $0.16 | — | — | $3.1M | — | +0.69% |
| May 8, 2026Q1 FY26 | — | $0.18 | — | — | $2.9M | — | +1.89% |
| Mar 27, 2026Q4 FY25 | — | $0.14 | — | — | $3.0M | — | +1.22% |
| Nov 6, 2025Q3 FY25 | — | $0.06 | — | — | $2.3M | — | −3.20% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.8M | $2.3M | $3.0M | $2.9M | $3.1M | |
| Gross profit | $1.4M | $1.5M | $925.8K | $1.3M | $1.4M | $1.5M | |
| Operating income | $610.9K | $695.5K | $215.1K | $721.9K | $642.4K | $754.1K | |
| Net income | $560.9K | $626.8K | $268.4K | $649.6K | $818.9K | $728.6K | |
| Diluted EPS | $0.12 | $0.14 | $0.06 | $0.14 | $0.18 | $0.16 | |
| Gross margin | 54.7% | 52.8% | 40.9% | 42.3% | 49.6% | 49.7% | |
| Operating margin | 24.6% | 24.5% | 9.5% | 24.4% | 22.4% | 24.3% |
Fiscal years (4-quarter sums)FY21 $13.9M · FY22 $12.7M · FY23 $10.9M · FY24 $12.2M · FY25 $10.5M
Balance sheet, Jun 30, 2026Cash & short-term investments $8.9M · Total debt $0 · Total assets $13.6M · Shareholders' equity $11.6M
Dividends
Raised for 2 straight years — most recently to $0.30 from $0.25 in Jul 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 28, 2026 | Jul 28 | Aug 4 | $0.30 | raised from $0.25 |
| Feb 9, 2026 | Feb 9 | Feb 17 | $0.25 | |
| Jul 25, 2025 | Jul 25 | Aug 1 | $0.25 | cut from $0.35 |
| Feb 10, 2025 | Feb 10 | Feb 18 | $0.35 | |
| Jul 23, 2024 | Jul 23 | Jul 31 | $0.35 | raised from $0.25 |
| Feb 9, 2024 | Feb 12 | Feb 20 | $0.25 | raised from $0.10 |
| Jul 25, 2023 | Jul 26 | Aug 2 | $0.10 | cut from $0.31 |
| Nov 25, 2022 | Nov 28 | Dec 7 | $0.31 | cut from $0.37 |
Ownership
Shares outstanding 4.59M · Float 2.96M · 64.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Kenneth H. Globus · director | 1.03M | 22.45% | Form 4 | Jan 23, 2026 |
| Renaissance Technologies LLC | 175.8K | 3.83% | 13F | May 14, 2026 |
| Gamco Investors, Inc. et al | 164.4K | 3.58% | 13F | May 14, 2026 |
| Vanguard Capital Management LLC | 128.3K | 2.79% | 13F | May 15, 2026 |
| Dimensional Fund Advisors LP | 68.5K | 1.49% | 13F | May 7, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Innospec
Beauty and personal-care formulation ingredients for product developers
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| United-Guardian | $7.15 | +0.70% | $32.8M | 13.2 | — | 2.9 | +9.5% |
| Innospec | $95.38 | −0.01% | $2.35B | 19.5 | 16.7 | 1.3 | +11.8% |
| Median | 19.5 | 16.7 | 1.3 | +11.8% |